Cargando…
Osteonectin as a screening marker for pancreatic cancer: A prospective study
OBJECTIVE: Osteonectin plays a central role in various processes during the development of pancreatic adenocarcinoma. This prospective pilot study was performed to determine the feasibility of serum osteonectin as a screening tool for pancreatic cancer. METHODS: Blood samples were collected from 15...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124255/ https://www.ncbi.nlm.nih.gov/pubmed/29756486 http://dx.doi.org/10.1177/0300060518772413 |
_version_ | 1783353004009717760 |
---|---|
author | Papapanagiotou, Angeliki Sgourakis, George Karkoulias, Kyriakos Raptis, Dimitris Parkin, Edward Brotzakis, Pantelis Panchal, Sanjay Papavassiliou, Athanasios G. |
author_facet | Papapanagiotou, Angeliki Sgourakis, George Karkoulias, Kyriakos Raptis, Dimitris Parkin, Edward Brotzakis, Pantelis Panchal, Sanjay Papavassiliou, Athanasios G. |
author_sort | Papapanagiotou, Angeliki |
collection | PubMed |
description | OBJECTIVE: Osteonectin plays a central role in various processes during the development of pancreatic adenocarcinoma. This prospective pilot study was performed to determine the feasibility of serum osteonectin as a screening tool for pancreatic cancer. METHODS: Blood samples were collected from 15 consecutive patients with newly diagnosed pancreatic cancer and 30 matched healthy controls. Serum osteonectin was measured using an osteonectin enzyme-linked immunosorbent assay kit. The primary outcomes were the diagnostic performance of serum osteonectin and the threshold value for differentiation of patients from controls. RESULTS: The median/quartile range of serum osteonectin in patients and controls were 306.8/288.5 ng/mL and 67.5/39.8 ng/mL, respectively. Osteonectin concentrations significantly differed among the study groups. A plasma osteonectin concentration of >100.18 ng/mL as selected by the receiver operating characteristic curves demonstrated an estimated area under the curve of 86% for prediction of pancreatic cancer. Tumour size was a significant predictor of serum osteonectin. A statistically significant difference in serum osteonectin between T1/T2 and T3/T4 tumours was found. Post-hoc comparisons revealed statistically significant differences in the serum osteonectin among the control, T1/T2, and T3/T4 groups. CONCLUSION: Osteonectin may be used as a screening tool for pancreatic cancer, although this must be validated in prospective studies. |
format | Online Article Text |
id | pubmed-6124255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-61242552018-09-10 Osteonectin as a screening marker for pancreatic cancer: A prospective study Papapanagiotou, Angeliki Sgourakis, George Karkoulias, Kyriakos Raptis, Dimitris Parkin, Edward Brotzakis, Pantelis Panchal, Sanjay Papavassiliou, Athanasios G. J Int Med Res Clinical Research Reports OBJECTIVE: Osteonectin plays a central role in various processes during the development of pancreatic adenocarcinoma. This prospective pilot study was performed to determine the feasibility of serum osteonectin as a screening tool for pancreatic cancer. METHODS: Blood samples were collected from 15 consecutive patients with newly diagnosed pancreatic cancer and 30 matched healthy controls. Serum osteonectin was measured using an osteonectin enzyme-linked immunosorbent assay kit. The primary outcomes were the diagnostic performance of serum osteonectin and the threshold value for differentiation of patients from controls. RESULTS: The median/quartile range of serum osteonectin in patients and controls were 306.8/288.5 ng/mL and 67.5/39.8 ng/mL, respectively. Osteonectin concentrations significantly differed among the study groups. A plasma osteonectin concentration of >100.18 ng/mL as selected by the receiver operating characteristic curves demonstrated an estimated area under the curve of 86% for prediction of pancreatic cancer. Tumour size was a significant predictor of serum osteonectin. A statistically significant difference in serum osteonectin between T1/T2 and T3/T4 tumours was found. Post-hoc comparisons revealed statistically significant differences in the serum osteonectin among the control, T1/T2, and T3/T4 groups. CONCLUSION: Osteonectin may be used as a screening tool for pancreatic cancer, although this must be validated in prospective studies. SAGE Publications 2018-05-13 2018-07 /pmc/articles/PMC6124255/ /pubmed/29756486 http://dx.doi.org/10.1177/0300060518772413 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Clinical Research Reports Papapanagiotou, Angeliki Sgourakis, George Karkoulias, Kyriakos Raptis, Dimitris Parkin, Edward Brotzakis, Pantelis Panchal, Sanjay Papavassiliou, Athanasios G. Osteonectin as a screening marker for pancreatic cancer: A prospective study |
title | Osteonectin as a screening marker for pancreatic cancer: A prospective study |
title_full | Osteonectin as a screening marker for pancreatic cancer: A prospective study |
title_fullStr | Osteonectin as a screening marker for pancreatic cancer: A prospective study |
title_full_unstemmed | Osteonectin as a screening marker for pancreatic cancer: A prospective study |
title_short | Osteonectin as a screening marker for pancreatic cancer: A prospective study |
title_sort | osteonectin as a screening marker for pancreatic cancer: a prospective study |
topic | Clinical Research Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124255/ https://www.ncbi.nlm.nih.gov/pubmed/29756486 http://dx.doi.org/10.1177/0300060518772413 |
work_keys_str_mv | AT papapanagiotouangeliki osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy AT sgourakisgeorge osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy AT karkouliaskyriakos osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy AT raptisdimitris osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy AT parkinedward osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy AT brotzakispantelis osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy AT panchalsanjay osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy AT papavassiliouathanasiosg osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy |